国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Policies

Healthcare on the cusp of big leap

By LIU ZHIHUA | China Daily | Updated: 2020-12-07 07:39
Share
Share - WeChat
Staff members inspect equipment at a production workshop of Novo Nordisk (China) Pharmaceuticals on Feb 25. The parent company will invest $30.5 million to set up a new unit at the Lingang Special Area of the China (Shanghai) Pilot Free Trade Zone. [Photo/Xinhua]

China's economic resilience, policy supports, long-term strategy attract big-ticket investments

Tailwinds are not only offsetting the negative economic impact of COVID-19 on China's healthcare industry but also speeding up its evolution, heralding restructuring, expansion and rise in foreign investment flows, industry insiders said.

The glad tidings promise to make health one of society's top priorities as the nation swears by the new dual-circulation pattern for high-quality development in the post-pandemic era.

A confluence of several factors-growing demand for higher-quality healthcare, improved protection for intellectual property rights, deepening of China's reform and opening-up, reinforced commitment to globalization, a business-friendly environment, integration of cutting-edge technologies into the medical field, new agreements for regional trade and economic cooperation, and a long-term national health strategy-h(huán)as created a near-perfect setting for the next big leap of the healthcare industry, they said.

To be sure, COVID-19 has caused massive job losses and a sharp fall in global foreign direct investment flows, but a quicker-than-expected economic recovery and remarkable resilience have made China one of the most attractive investment destinations in the global healthcare industry.

For instance, during the third China International Import Expo in early November in Shanghai, Novo Nordisk, a global healthcare leader in diabetes treatment, announced it will invest 200 million yuan ($30.5 million) to establish a new facility at the Lingang Special Area of the China (Shanghai) Pilot Free Trade Zone.

Novo Nordisk's new unit will foray into several market segments, including marketing, pharmaceutical research and development, and finished goods imports and distribution.

"The excellent business environment and preferential policy support in the Lingang Special Area will allow this new entity to become a powerful driver of Novo Nordisk's strategy of solidifying its value chain in China," the company said in a statement.

1 2 Next   >>|
Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
垣曲县| 葫芦岛市| 奉节县| 司法| 商都县| 大宁县| 陈巴尔虎旗| 重庆市| 盈江县| 英德市| 延津县| 太湖县| 成安县| 汉阴县| 高要市| 修水县| 昌图县| 正宁县| 潮安县| 海伦市| 青铜峡市| 宾川县| 焦作市| 灵丘县| 专栏| 苍山县| 南宫市| 确山县| 山阴县| 金堂县| 三河市| 西充县| 赤峰市| 济源市| 阜康市| 张家港市| 清涧县| 双城市| 佛冈县| 出国| 淮南市|